X4 Pharmaceuticals Report Positive Results from Clinical Trial Treating Advanced Clear Cell Renal Cell Carcinoma Patients

X4 Pharmaceuticals Report Positive Results from Clinical Trial Treating Advanced Clear Cell Renal Cell Carcinoma Patients

Subgroup exceeds target of 50% improvement in median progression-free survival, and 12% of patients remain on combination treatment with durations of 17 months or longer in X4 Pharmaceuticals’ Phase 2a portion of its open-label Phase 1/2 clinical trial of mavorixafor...

Pin It on Pinterest